

SPONSORSHIP AGREEMENT

This sponsorship agreement (the "Agreement") is made effective as of 4. July 2021 (the "Effective Date"), between Swedish Orphan Biovitrum A/S, Sorgenfrivej 17, 2800 Lyngby ("Sobi") and Danmarks Bløderforening ("Recipient").

WHEREAS, Sobi A/S is an affiliate of an international biopharmaceutical company dedicated to rare diseases;

WHEREAS, Recipient is Danmarks Bløderforening; and

WHEREAS, Sobi has agreed to sponsor Danmarks Bløderforenings Study of quality of life among Danish patients with bleeding disorders (the "Meeting") on the terms and conditions set out below.

NOW, THEREFORE, the parties agree as follows:

1. TERMS AND CONDITIONS OF SPONSORSHIP

- 1.1 **Sponsorship:** Sobi hereby agrees to provide Recipient the sum of 45.657 DKK (fortyfive thousand six hundred fifty seven) + applicable VAT for the purpose of (the "Sponsorship").
- 1.2 **Scope:** The Sponsorship shall only cover actual, documented, reasonable and direct costs that are necessary in order to carry out the professional parts of the Meeting, as further specified in Schedule 1. Activities and materials generated as a result of this Sponsorship shall comply with all applicable laws and regulations.
- 1.3 **Meeting Budget and Repayment:** Recipient have provided Sobi with a complete budget for the Meeting. Unused budget resources shall be repaid to Sobi without delay after the Meeting or immediately if the Meeting is cancelled.
- 1.4 **Benefits of Sponsorship:** In return for Sobi sponsoring the Meeting Recipient shall provide Sobi with the benefits specified in Schedule 2.
- 1.5 **Payment:** The Sponsorship will be paid in the following instalments..
- 1.6 **Payment Terms:** All payments hereunder shall be made within thirty (30) days via bank transfer or from receipt of invoice provided that the following conditions shall have been met: invoices shall be specified as to Sobi contact person Julie Trolle. Sobi's invoice address is: Sobi, Sorgenfrivej 17, 2800 Lyngby.

Sobi shall pay Recipient by electronic bank transfer in accordance with the above agreed payment schedule.

- 1.7 **Communication:** Well before the Meeting, Recipient shall communicate the names of all sponsors. Sobi will be transparent regarding its support of the Meeting and the Recipient agrees to be similarly transparent. The Sponsorship will be acknowledged by the Recipient and made clear on all materials as further specified in Schedule 2. Participants' invitations shall state the Recipient as the organizer, the purpose of the Meeting activities and identify as sponsors Sobi and any other pharmaceutical companies which sponsor the Meeting
- 1.8 **Use of Sobi name:** Recipient shall only use the name and logotypes of Sobi, in publications, presentations, programmes, other printed or orally presented materials or otherwise, after prior review and approval of Sobi.
- 1.9 **No inducement:** Recipient acknowledges that provision of the Sponsorship is in no way an inducement to recommend, prescribe, purchase, supply, sell or administer a particular medicinal product.
- 1.10 **Hospitality, programme and venue of the Meeting:** The Recipient represents and warrants to Sobi that
- (a) Hospitality made directly or indirectly available during the Meeting shall be kept at a reasonable level and remain secondary to the principal scientific purpose of the Meeting, be limited to the organisation and/or defrayment of the costs of travel, meals, accommodation and registration, shall not extend beyond the official duration of the Meeting and shall not include payment for or the organization of sports or leisure activities or any other form of entertainment;
 - (b) The value of meals provided, drinks included, shall not exceed the limits laid down by Applicable Law, including applicable local industry guidelines;
 - (c) The Meeting shall be predominantly scientific in nature and activities with a scientific purpose shall, in terms of time, take up the greater part of each day of the Meeting; and
 - (d) The Meeting shall take place at a suitable venue that aids the scientific purpose of the event and the place, date and duration of the Meeting and travel shall not in any case be of a nature to create any confusion as to its scientific nature.

2. MISCELLANEOUS PROVISIONS

- 2.1 Entire Agreement:** This Agreement, including its Schedules, constitutes the entire understanding between the parties with respect to the subject matter hereof and supersedes all prior oral or written agreements of the parties with respect to such subject matter
- 2.2 Amendments:** No provision of this Agreement may be amended, modified or otherwise changed, other than by an instrument in writing duly executed on behalf of the parties to this Agreement.
- 2.3 Assignments:** This Agreement is personal to the parties who shall not have any right to assign it without the prior written consent of the other party, except that Sobi shall have the right to assign the Agreement to its affiliates.
- 2.4 Independent Contractors:** In making and performing this Agreement, the parties are acting and shall act at all times as independent contractors, and nothing contained in this Agreement shall be construed or implied to create any agency, partnership or employer and employee relationship between Sobi and Recipient. At no time shall any party make commitments or incur any charges or expenses for or in the name of any other party, other than as expressly set forth herein.

3. PROCESSING OF PERSONAL DATA

- 3.1** The General Data Protection Regulation ("GDPR") requires that Sobi provides Recipient notice of Sobi's processing of personal data about Recipient.
- 3.2** The Sobi entity which is party to this Agreement is data controller for the processing of Recipient's personal data.
- 3.3** Sobi processes the personal data provided by Recipient with a view to administer this Agreement, including payment of any agreed compensation. The basis for the processing is Article 6(1)(b) of the GDPR as processing of Recipient's personal data is necessary for the performance of this Agreement.
- 3.4** Furthermore, Sobi may store Recipient's contact information in a database for the purpose of engaging Recipient as a future speaker, for meetings and training events and similar services. Sobi may also process Recipient's personal data for internal evaluation purposes. Such processing is based on Article 6(1)(f) of the

GDPR as Sobi has a legitimate interest in maintaining the relationship with Recipient and improving Sobi's products.

- 3.5 Sobi may also process Recipient's personal data for the dispatch of e-mails regarding upcoming event, invitations, new products, etc. Sobi will obtain Recipient's prior consent, should it be required. In such case, the processing is based on Article 6(1)(a) of the GDPR.
- 3.6 Recipient's name may be published on invitations to the Event. Such processing is based on Article 6(1)(f) of the GDPR as Sobi has a legitimate interest in publishing the content of the Event.
- 3.7 To meet the purposes mentioned above, Sobi may share Recipient's personal data within the Sobi group and with Sobi service providers, e.g. IT system providers, and agents.
- 3.8 Such sharing may include transfer to third countries, i.e. countries outside the EU/EEA area. When transferring Recipient's personal data to third countries, Sobi will ensure that the transfer is subject to appropriate safeguards and that Recipient's rights are protected. Typically, Sobi will enter into standard contractual clauses adopted by the EU Commission with companies in third countries receiving personal data from Sobi.
- 3.9 In general, Sobi deletes Recipient's personal data when Sobi no longer needs them to meet the purposes mentioned above.
- 3.9 As a main rule, Sobi stores personal data on Recipient for a period of 2 years from latest engagement of Recipient or latest communication with Recipient. If Recipient's social security registration number is collected, such data will be deleted after reporting to the relevant government entities/public authorities. Personal data which must be stored under the Danish Bookkeeping Act will be deleted 5 years after the end of the relevant financial year.
- 3.10 The personal data may, however, be processed and kept for a longer period in anonymised form or if Sobi is required to do so by law.
- 3.11 Recipient has the right to access the personal data that Sobi processes concerning the Recipient and to request that Sobi rectifies any inaccurate personal data and under certain circumstances request erasure and/or restriction of processing of the personal data. Recipient has the right to object to processing and to receive the processed personal data in a structured, commonly used and machine-readable format and has the right to transmit those data to another data controller. Provided that Sobi is a legal entity with a registered office in an EU member

state, Recipient also has the right to lodge a complaint to the supervisory authority The Danish Data Protection Agency regarding Sobi's processing of Recipient's personal data.

4. GOVERNING LAW AND JURISDICTION


This Agreement shall be governed and construed by the substantive laws of Denmark. Any dispute, controversy or claim arising out of or in connection with this Agreement, or the breach, termination or invalidity thereof, shall be finally settled by the courts of the above said country.


[Signatures to follow on the next page.]

This Agreement has been signed by each party's duly authorized signatory(ies). This Agreement may be executed and transmitted via email in Portable Document Format (PDF), and in counterparts, each of which taken together, shall constitute one agreement binding on the parties with the same force and effect as an original signed agreement.

Mai Clifford

Karen Binger Holm


Name: Mai Clifford
Title: Country Manager
Date: 8/7 - 2021


Danmarks Bløderforening
Køpmønstestræde 22, 2.
1208 København K
Tlf. 33 14 55 05
CVR-nr. 11 80 29 90
Name: Karen Binger Holm
Title: Head of the Secretariat
Date: 16.8.2021

SCHEDULE 1

SPONSORSHIP AND COSTS

Sobi will sponsor 45.657 DKK to Danmarks Bløderforenings Study of quality of life among Danish patients with bleeding disorders.

Budget og finansiering

Budget	Note	DKK
Databearbejdning, analyse og formidling	588 timer á 450 kr., Københavns Universitet	264.600 kr.
Opsætning og datatræk i SurveyXact	200 timer á 275 kr., Københavns Universitet	55.000 kr.
Udsendelse via centrene	Sekretærbistand til udsendelse via e-boks á 10.000 kr., AUH og Rigshospitalet	20.000 kr.
Artikelsgebyr		30.000 kr.
Projektledelse Danmarks Bløderforening		50.000 kr.
I alt		419.600 kr.

Hoffmanns og Husmans Fond har bevilget 100.000 kr. Restfinansieringen søges gennem tilskud fra medicinalfirmaer med produkter til behandling af hæmofili og von Willebrands sygdom. Der søges i alt om støtte på 319.600 kr., estimeret til 45.657 kr. pr. firma.

Tidsplan

Udgangspunktet er at der i september 2022 vil kunne præsenteres data om danske blødere når den europæiske paraplyorganisation for blødere European Haemophilia Consortium (EHC) afholder sin årlige konference i København.

Milestones:

- Formulere og revidere spørgeskema i august-september 2021
- Undersøgelsen gennemføres i oktober 2021
- Data renses og bearbejdes i november-december 2021
- Artikler skrives januar-april 2022 (udarbejdelse af to artikler)
- Rapport skrives i maj-juni og sendes til følgegruppe midt juni 2022
- Revideret rapport og forberedelse til konference august-september (ferie i juli) 2022

Eftersom data der præsenteres på konferencer skal være publiceret i videnskabelige artikler afsættes tid til artikler før rapportskrivning.

Formidling

Når data er indsamlet og renses vil de blive formidlet i artikelformat, en rapport med opfølgning på de tidligere undersøgelser og præsenteres på konference i København i efteråret 2022. Artikler skrives i januar-april og deles med følgegruppe undervejs i arbejdet.

SCHEDULE 2

BENEFITS OF THE SPONSORSHIP

By supporting the Study of quality of life among Danish patients with bleeding disorders, we will get a picture of the situation and benefit of the increased treatment for persons with haemophilia. This QoL study is no. 4 – the first study was conducted in 1988, no. 2 in 2001, no. 3 in 2012.

The data will be presented in scientific publications and at relevant congresses.

The report is available late 2022.